Shots:
Eli Lilly has entered into a definitive agreement to acquire CrossBridge Bio, incl. its synergistic dual payload platform for the development of differentiated therapeutics
As per the deal, Lilly will acquire CrossBridge Bio for ~$300M in cash, incl. an upfront payment & a subsequent milestone payment
CrossBridge Bio is advancing CBB-120, a TROP2-targeting TOP1i/ATRi…
